Eribulin mesylate in the treatment of metastatic breast cancer

The treatment of metastatic breast cancer (MBC) has become increasingly challenging as the primary goals of therapy include prolonging life without added toxicity. While multiple agents are approved for the therapy of MBC, there is no standard approach for therapy beyond the second-line. Eribulin me...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Sarika, Cigler, Tessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266863/
https://www.ncbi.nlm.nih.gov/pubmed/22291464
http://dx.doi.org/10.2147/BTT.S19811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266863/
https://www.ncbi.nlm.nih.gov/pubmed/22291464
http://dx.doi.org/10.2147/BTT.S19811

Ejemplares similares